Purdue Pharma and Sackler Family Reach $7.4 Billion Settlement Over Opioid Crisis
Purdue Pharma, the company behind the controversial painkiller OxyContin, along with members of the Sackler family, has agreed to a new settlement totaling $7.4 billion to resolve numerous lawsuits related to the opioid crisis. New York Attorney General Letitia James announced this development on Thursday, marking a significant increase from a previously rejected settlement.
This settlement, which needs court approval, addresses claims from state and local governments as well as thousands of victims affected by the opioid epidemic. The Sackler family will contribute up to $7.4 billion over the next 15 years while relinquishing ownership of Purdue, which will transition to a new entity governed by appointees from the suing parties.
The settlement also earmarks funds for victims of the opioid crisis and their families. The agreed amount surpasses the $6 billion previously proposed, which was blocked by the U.S. Supreme Court due to its protective clauses for the Sackler family against civil lawsuits. The revised agreement protects family members only from lawsuits initiated by parties accepting the settlement.
This new deal could potentially conclude a lengthy legal struggle stemming from OxyContin's association with a significant rise in opioid addiction and related fatalities since its introduction in 1996. The opioid crisis has led to hundreds of thousands of deaths in the U.S., significantly exacerbated since 2020 by illicit fentanyl.
The Sacklers have faced substantial public criticism and their name has been removed from various cultural institutions as a result of the opioid crisis. Despite their immense wealth, much of which is held in offshore accounts, they continue to deny any wrongdoing related to the crisis.
Weekly Newsletter
News summary by melangenews